EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 424 filers reported holding EXELIXIS INC in Q4 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,775,130 | +43.3% | 79,000 | +51.3% | 0.02% | +46.2% |
Q1 2024 | $1,238,706 | -1.1% | 52,200 | 0.0% | 0.01% | +8.3% |
Q4 2023 | $1,252,278 | +9.8% | 52,200 | 0.0% | 0.01% | 0.0% |
Q3 2023 | $1,140,570 | -83.8% | 52,200 | -85.8% | 0.01% | -82.6% |
Q2 2023 | $7,018,988 | -6.3% | 367,294 | -4.9% | 0.07% | -5.5% |
Q1 2023 | $7,494,085 | +82.8% | 386,094 | +51.1% | 0.07% | +102.8% |
Q4 2022 | $4,099,327 | +45.8% | 255,569 | +42.5% | 0.04% | +63.6% |
Q3 2022 | $2,812,000 | -23.3% | 179,325 | +1.8% | 0.02% | -15.4% |
Q2 2022 | $3,668,000 | +56.6% | 176,155 | +70.5% | 0.03% | +100.0% |
Q1 2022 | $2,342,000 | +139.5% | 103,291 | +158.2% | 0.01% | +18.2% |
Q3 2020 | $978,000 | +2.9% | 40,000 | 0.0% | 0.01% | 0.0% |
Q2 2020 | $950,000 | +47.7% | 40,000 | +22.3% | 0.01% | +57.1% |
Q4 2018 | $643,000 | +218.3% | 32,700 | +186.8% | 0.01% | +250.0% |
Q3 2018 | $202,000 | -59.4% | 11,400 | -50.6% | 0.00% | -50.0% |
Q2 2018 | $497,000 | +126.9% | 23,100 | +159.6% | 0.00% | +100.0% |
Q2 2017 | $219,000 | – | 8,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |